Search filters

Filters
Clear All

Phase

  • 2
  • 4
  • 6
  • 5
  • 6

Found 6 Scleroderma trials

A listing of Scleroderma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Sort by:
99 years or below
All genders
Systemic sclerosis (SSc) is a rare, chronic, autoimmune, connective tissue disease with one of the highest mortality rates among rheumatic diseases. Objective of the study is to evaluate the efficacy of efgartigimod for SC administration coformulated with rHuPH20 (efgartigimod PH20 SC) compared with placebo (placebo PH20 SC) on skin sclerosis …
99 years or below
All genders
Phase 3
Systemic sclerosis is a rare chronic autoimmune connective tissue disease. B cells have been reported to play a central role in the pathogenesis of SSc and B cell depletion has been shown to offer benefit to patients with SSc. Belimumab is a monoclonal antibody, which inhibits the survival of B …
99 years or below
All genders
This is a platform study to assess the safety and efficacy of investigational products in participants with interstitial lung disease that is secondary to systemic sclerosis.
21 years or above
All genders
Phase 3
Interventional
This study investigates Progressive Pulmonary Fibrosis. The study focuses on understanding how the investigational medication works for this condition.This study evaluates the safety, effectiveness, and tolerability of the investigational medication. It looks into how well participants respond to the treatment.Who can participate: Adults diagnosed with interstitial lung disease (ILD) showing …
99 years or below
All genders
This study is an open label extension study of an ongoing randomized controlled clinical study, 218224 which aims to assess the efficacy of belimumab on reducing the decline in lung function in participants with interstitial lung disease associated with diffuse cutaneous systemic sclerosis.
99 years or below
All genders
Our goal is to identify markers which can predict response to therapy in patients with dermatomyositis, systemic sclerosis, lupus erythematosus, morphea, eosinophilic fasciitis, and other immune-mediated cutaneous and rheumatic diseases. To collect human tissue from lesional and non-lesional skin, as well as blood, cheek swabs, photographs of biopsy site(s) or …